

# PRODUCT INFORMATION



## 1-Palmityl-2-hydroxy-*sn*-glycero-3-PA (sodium salt)

Item No. 10010292

**Formal Name:** 3-(hexadecyloxy)-1-(dihydrogen phosphate)-1,2-propanediol, monosodium salt

**Synonyms:** 1-Hexadecyl-2-hydroxy-*sn*-glycero-3-phosphate, 1-Hexadecyl LPA, 1-Hexadecyl Lysophosphatidic Acid, LPA O-16:0, O-16:0 LPA, PA(O-16:0/0:0), 1-Palmityl LPA, 1-Palmityl Lysophosphatidic Acid

**MF:** C<sub>19</sub>H<sub>40</sub>O<sub>6</sub>P • Na


**FW:** 418.5

**Purity:** ≥98%

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

1-Palmityl-2-hydroxy-*sn*-glycero-3-PA (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the 1-palmityl-2-hydroxy-*sn*-glycero-3-PA (sodium salt) in the solvent of choice, which should be purged with an inert gas. 1-Palmityl-2-hydroxy-*sn*-glycero-3-PA (sodium salt) is soluble in a solution of chloroform:methanol:acetic acid (95:5:5).

### Description

1-Palmityl-2-hydroxy-*sn*-glycero-3-PA (sodium salt) is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group at the *sn*-1 position.<sup>1</sup> LPA binds to five different G protein-coupled receptors to mediate a variety of biological responses including cell proliferation, smooth muscle contraction, platelet aggregation, neurite retraction, and cell motility.<sup>2,3</sup>

### References

1. Tsukahara, T., Tsukahara, R., Yasuda, S., *et al.* Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor  $\gamma$ . *J. Biol. Chem.* **281**(6), 3398-3407 (2006).
2. Moolenaar, W.H. LPA: A novel lipid mediator with diverse biological actions. *Trends Cell Biol.* **4**(6), 213-219 (1994).
3. Chun, J., Goetzl, E.J., Hla, T., *et al.* International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. *Pharmacol. Rev.* **54**(2), 265-269 (2002).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/26/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM